(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    Int J Stem Cells, 2018, 11(1):131-140. (+)-JQ1 purchased from Selleck.

  • JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

    immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

  • Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  M1jpTWNmdGxiVnnhZoltcXS7IFHzd4F6 MV6yOVAwPTByL{GwNFAhdk1? NEPscZozPC92OD:3NkBp MmnXSG1UVw>? MnnxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NEOwclUzPjdyN{i4NS=>
BCPAP NIjEWpFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVj4N4o{OjVyL{WwNE8yODByIH7N Mn3oNlQwPDhxN{KgbC=> NF62Uo1FVVOR NUnQbmRncW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? MWKyOlcxPzh6MR?=
K1  MVHD[YxtKEO7Y3zlJGF{e2G7 NFXWSGkzPTBxNUCwM|ExODBibl2= Mmq0O|IhcA>? NInnTnBFVVOR MkfTZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn MVuyOlcxPzh6MR?=
BCPAP NIq1VotE\WyuIFP5Z4xmKEG|c3H5 M2\yRlI2OC93MECvNVAxOCCwTR?= MnSzO|IhcA>? NHe4WodFVVOR MVrhdpJme3S|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V? NUDhXmFlOjZ5MEe4PFE>
Hep3B M4[xN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvHSWZCOC1zMDFOwG0> NXrRRmRqPSCm M1vXcWROW09? NEjnW5pKSzVyPUCuNFgh|ryP MXOyOlU4PTF4Nx?=
HCCLM3 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHZZpdPOC1zMDFOwG0> NIOz[Hk2KGR? NFu1b41FVVOR MnvwTWM2OD1yLkG0JO69VQ>? NWfZUFl6OjZ3N{WxOlc>
HuH7 NEHFWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXnNoh3OC1zMDFOwG0> MkmzOUBl MoTZSG1UVw>? M1PRXGlEPTB;MD6yNUDPxE1? NILSO5UzPjV5NUG2Oy=>
HepG2 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES5WpgxNTFyIN88US=> M{Lk[FUh\A>? M4WwWGROW09? M1LXbWlEPTB;MD6zOEDPxE1? NHfBWXMzPjV5NUG2Oy=>
SMMC7721 NX;6eJJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXKdoZpOC1zMDFOwG0> MXe1JIQ> NV3aO|IzTE2VTx?= M2X4SGlEPTB;MD60NUDPxE1? MnjZNlY2PzVzNke=
BEL7402 MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXaUotbOC1zMDFOwG0> MXm1JIQ> NU\RPJJqTE2VTx?= MUfJR|UxRTBwNEeg{txO NF7kUlEzPjV5NUG2Oy=>
MHCC97H M4T1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\jPJZyOC1zMDFOwG0> NFfafHM2KGR? MVXEUXNQ M4ixVmlEPTB;MD60NUDPxE1? NWjke3NxOjZ3N{WxOlc>
Hep3B NVnYR5NQS2WubDDDfYNt\SCDc4PhfS=> M3XFRVAvOS9yLkWvNk42KM7:TR?= M1rpblQ5KGh? MX\EUXNQ MUDs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> NGjMN4ozPjV5NUG2Oy=>
HCCLM3 NF3QXnhE\WyuIFP5Z4xmKEG|c3H5 MojzNE4yNzBwNT:yMlUh|ryP NVq5U|JCPDhiaB?= NWC2UZpyTE2VTx?= NWP4TJRVdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy|IHnuJJN2[i2JMTDwbIF{\cLi MUSyOlU4PTF4Nx?=
Hep3B NX;kS414SXCxcITvd4l{KEG|c3H5 MkDxNE4yNzBwNT:yMlUh|ryP NYHy[4s4PDhiaB?= MWLEUXNQ MnLYZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? NXvCO5pCOjZ3N{WxOlc>
HCCLM3 NInMUplCeG:ydH;zbZMhSXO|YYm= Mo\0NE4yNzBwNT:yMlUh|ryP NV\ReWVMPDhiaB?= NIW3TIJFVVOR M4rESIFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? MmnFNlY2PzVzNke=
A549 NHewbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWwMlEuOTBizszN NELVUno4OiCq NHzET5RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlHXNlY1OTV{MkW=
H157 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;2NE4yNTFyIN88US=> MkXaO|IhcA>? NH3CfG5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnTLNlY1OTV{MkW=
H1299 NGfCWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe4SmN3OC5zLUGwJO69VQ>? M{G0cFczKGh? NVPsbVBKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUKyOlQyPTJ{NR?=
A549 MnW2SpVv[3Srb36gRZN{[Xl? NILMcHMyNzJwNT:1JO69VQ>? NEDl[IQyOiCq MlvPxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? M163T|I3PDF3MkK1
H1299 NIqy[ZFHfW6ldHnvckBCe3OjeR?= MXOxM|IvPS93IN88US=> MXWxNkBp NHLnT2bDqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy| MXyyOlQyPTJ{NR?=
H157 NXLndnU6TnWwY4Tpc44hSXO|YYm= M3fyW|EwOi53L{Wg{txO NYrxSXFvOTJiaB?= MUDk[YNz\WG|ZXSgSHI1KGW6cILld5Nqd25? NWK1SHB5OjZ2MUWyNlU>
H1299 MYHGeY5kfGmxbjDBd5NigQ>? NGDvVIUyNzJwNT:1JO69VQ>? MnO4NVIhcA>? M3TxfYRm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?= MXWyOlQyPTJ{NR?=
C8161 NXLadVRDS2WubDDWbYFjcWyrdImgRZN{[Xl? M1WzclAuOiEQvF2= NWjuTo9rPCCm NUj1OVZOTE2VTx?= MV;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWiyOlM6PzJ{Mx?=
Mel285 NUjO[|FWS2WubDDWbYFjcWyrdImgRZN{[Xl? MUKwMVIh|ryP MV[0JIQ> M4KzRWROW09? NFvSbmxl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmT5NlY{QTd{MkO=
Mel290 M1\0NmNmdGxiVnnhZoltcXS7IFHzd4F6 NWTF[2JtOC1{IN88US=> M2PNd|Qh\A>? MVnEUXNQ M{Lvb4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYqzbWF1OjZ|OUeyNlM>
92.1 NGeyXJRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFToO|YxNTJizszN MoXOOEBl NGG0WXpFVVOR MX7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{\C[lI3Ozl5MkKz
Omm1.3 NVq2VnpxS2WubDDWbYFjcWyrdImgRZN{[Xl? MWewMVIh|ryP NWH3VlRuPCCm NEDyV|VFVVOR NI\4cYJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVOyOlM6PzJ{Mx?=
Mel202 MmfER4VtdCCYaXHibYxqfHliQYPzZZk> M37VV|AuOiEQvF2= MX[0JIQ> MmWySG1UVw>? MWPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1LHVFI3Ozl5MkKz
Mel270 NIfBT4xE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUm4XYk5OC1{IN88US=> MWW0JIQ> MnPBSG1UVw>? M1;oNoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXq5NVE4OjZ|OUeyNlM>
Omm1 MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2HGWFAuOiEQvF2= M{fhdVQh\A>? NYf3d29JTE2VTx?= MYLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn\xNlY{QTd{MkO=
92.1 M4Tyd2Fxd3C2b4Ppd{BCe3OjeR?= MYK1NFAhdk1? Mo\nOFghcA>? MkDKSG1UVw>? MmOybY5lfWOnczDhdI9xfG:|aYO= M2DtcFI3Ozl5MkKz
Omm1.3 M3W1WmFxd3C2b4Ppd{BCe3OjeR?= MVO1NFAhdk1? Mn;FOFghcA>? M2\rTWROW09? MkLWbY5lfWOnczDhdI9xfG:|aYO= M{LQ[FI3Ozl5MkKz
92.1 M1LOTWNmdGxiQ4njcIUhSXO|YYm= MVq1NFAhdk1? MVuyOE81QC95MjDo MVfEUXNQ NWTH[GFwcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= MXeyOlM6PzJ{Mx?=
Omm1.3 MWrD[YxtKEO7Y3zlJGF{e2G7 MVS1NFAhdk1? MXGyOE81QC95MjDo MYXEUXNQ M{DtTIlv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi MmDqNlY{QTd{MkO=
A549 MVzGeY5kfGmxbjDBd5NigQ>? NHqxenMyODBxNECwM|ExODBibl2= MmfhNlQhcA>? M1LubJVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? NF[1c3IzPjJzMkG5PS=>
MCF-7 MX\GeY5kfGmxbjDBd5NigQ>? NXfxdZd2OTByL{SwNE8yODByIH7N MmLUNlQhcA>? MVP1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy MUSyOlIyOjF7OR?=
HEK293 MWXGeY5kfGmxbjDBd5NigQ>? MXmxNFAwPDByL{GwNFAhdk1? MoLlNlQhcA>? NV7nNlBNfXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= NX;1UZB6OjZ{MUKxPVk>
858 NHPRSVNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3;zfVAuOSEQvF2= MlXxOUBl NF61XnZFVVOR MVPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXWyOlIxPjN|Mx?=
DDR2L63V M3rJcmNmdGxiVnnhZoltcXS7IFHzd4F6 MkWxNE0yKM7:TR?= NH3TRVE2KGR? Mli0SG1UVw>? NXPDTGdj\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkfnNlYzODZ|M{O=
BE(2)-C MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4\6dlEh|ryP MXexMVQh\A>? NI[3[nll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MVKyOlA3PzR4NB?=
IMR-32 M4DYVWNmdGxiVnnhZoltcXS7IFHzd4F6 NEDDW|MyKM7:TR?= MlvsNU01KGR? M{XaNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 M3HrVVI3ODZ5NE[0
JF M2i1SGNmdGxiVnnhZoltcXS7IFHzd4F6 MWixJO69VQ>? MX6xMVQh\A>? NVexNFhE\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MXuyOlA3PzR4NB?=
BE(2)-M17 NWL5THdPS2WubDDWbYFjcWyrdImgRZN{[Xl? MVmxJO69VQ>? MnLPNU01KGR? Moq0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> M3[2SVI3ODZ5NE[0
SK-N-SH NHTWVXRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3Pnc|Eh|ryP NWGyPYRZOS12IHS= NXvQc3J2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MX[yOlA3PzR4NB?=
SK-N-DZ  NH:5dolE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVSxJO69VQ>? MU[xMVQh\A>? Ml[0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MVuyOlA3PzR4NB?=
HMC-1.1  MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm1MVUxODBibl2= NFzwc3Q1QCCq MYLEUXNQ MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVyyOlA2PTNyMx?=
HMC-1.2 M2K0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUG1MVUxODBibl2= Ml[2OFghcA>? NUTLfmczTE2VTx?= NW\lWItqcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWmyOlA2PTNyMx?=
ROSA KIT WT  MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj5VXpDPS13MECwJI5O NEHIeXo1QCCq MnX5SG1UVw>? NIHFZWdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYCyOlA2PTNyMx?=
ROSA KIT D816V NGjKWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\penV7PS13MECwJI5O MmjJOFghcA>? MWLEUXNQ M{HCeIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1nFdlI3ODV3M{Cz
HMC-1.1  NIHPeY9CeG:ydH;zbZMhSXO|YYm= MV:yNFAuPTByMDDuUS=> M1v2UlQ5KGh? NI\zT|ZFVVOR MYXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmDaNlYxPTV|MEO=
HMC-1.2 MmLrRZBweHSxc3nzJGF{e2G7 M1ruflIxOC13MECwJI5O NUi2bYpEPDhiaB?= MlXuSG1UVw>? M1u1W4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2G5[FI3ODV3M{Cz
ROSA KIT WT  NH;MS3ZCeG:ydH;zbZMhSXO|YYm= NILLb3EzODBvNUCwNEBvVQ>? MXG0PEBp NIrCNnFFVVOR NWfNSWxMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmHDNlYxPTV|MEO=
ROSA KIT D816V NH32R3hCeG:ydH;zbZMhSXO|YYm= MkjCNlAxNTVyMECgcm0> MoPWOFghcA>? MkXmSG1UVw>? M1rPfIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYrSeFRQOjZyNUWzNFM>
494H MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PJeFczKGh? NXzISJl7TE2VTx?= NV3Te5JVUUN3ME2wMlEzOsLzMD6wNFQh|ryP M33SS|I2QTR2NU[2
493H MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUe3NkBp NWXDVmloTE2VTx?= NEnw[mRKSzVyPUCuNFQ4yrFyLkCwPUDPxE1? MmDxNlU6PDR3Nk[=
716H MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTtO|IhcA>? Mke1SG1UVw>? NULwTHloUUN3ME2wMlIyOsLzMD6wN|Qh|ryP NXrO[lhCOjV7NES1OlY>
148I MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjzUII4OiCq NIL6UW5FVVOR M2Dtc2lEPTB;MD6yPFTDuTBwMEO1JO69VQ>? M3raRlI2QTR2NU[2
98Sc NWf0bGtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXu3NkBp Mnn2SG1UVw>? MWLJR|UxRTBwMUG1xtExNjByNDFOwG0> MXiyOVk1PDV4Nh?=
89R NUf5T|JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX23NkBp NV7sR2xiTE2VTx?= NUPOVmYyUUN3ME2wMlEzPsLzMD6wNFMh|ryP MVmyOVk1PDV4Nh?=
494L NH\ONnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zTOlczKGh? NHTEZXdFVVOR MX;JR|UxRTBwM{G3xtExNjBzMjFOwG0> MV2yOVk1PDV4Nh?=
493L MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV2yenJbPzJiaB?= NYnSXGZuTE2VTx?= M4[4UGlEPTB;MD6wOVDDuTBwMEGxJO69VQ>? MVSyOVk1PDV4Nh?=
148L M1r0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\mSo03PzJiaB?= NVTNN3R1TE2VTx?= MmixTWM2OD1yLkG0OuKyOC5yMUeg{txO MlzjNlU6PDR3Nk[=
98L MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorMO|IhcA>? MVrEUXNQ M2f1bGlEPTB;MD6zNFnDuTBwMEK5JO69VQ>? NV;PUHc5OjV7NES1OlY>
OS17 NVOwXIl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLHXIxNPzJiaB?= MofNSG1UVw>? NVvZTI9RUUN3ME2wMlA4QcLzMD6wNFMh|ryP NWXhb5FzOjV7NES1OlY>
OS9 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG3NkBp NXzDUZNxTE2VTx?= NF75[3dKSzVyPUCuOFA3yrFyLkCyPEDPxE1? MX6yOVk1PDV4Nh?=
MG63 M4LZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[3NkBp NUDjS|lITE2VTx?= NF3zSHJKSzVyPUCuNVE1yrFyLkCyOUDPxE1? NGH1eVIzPTl2NEW2Oi=>
SAOS2 Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVG3NkBp MXrEUXNQ MWnJR|UxRTBwMkG3xtExNjByMzFOwG0> MkDxNlU6PDR3Nk[=
U2OS MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHviSHk4OiCq M{jUfmROW09? NEnDXZVKSzVyPUCuNVk5yrFyLkCwPEDPxE1? NYWyXIM5OjV7NES1OlY>
SJSA-1 NX3ETXhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr5OFlzPzJiaB?= M{WwPWROW09? M3zuXWlEPTB;MD6xNFDDuTBwMEGwJO69VQ>? NWf6eWlZOjV7NES1OlY>
494H MY\BdI9xfG:|aYOgRZN{[Xl? MlfLNE4zPS9yLkWvNU4xKM7:TR?= NHe4elEzPCCq MlOySG1UVw>? MkKybY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh M1LPc|I2QTR2NU[2
148I NXPIeJlGSXCxcITvd4l{KEG|c3H5 NGD0eoQxNjJ3L{CuOU8yNjBizszN NFrsTFkzPCCq MYXEUXNQ NIjvZoJqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? MXeyOVk1PDV4Nh?=
OS17 MoP5RZBweHSxc3nzJGF{e2G7 M1LHZVAvOjVxMD61M|EvOCEQvF2= NVnRbmhDOjRiaB?= MonISG1UVw>? MmrEbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh MmXyNlU6PDR3Nk[=
494H MnzjRZBweHSxc3nzJGF{e2G7 MnTINgKBkc7:TR?= NF74R4g1QCCq MX;EUXNQ MXPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= MUSyOVk1PDV4Nh?=
148I MW\BdI9xfG:|aYOgRZN{[Xl? MlHLNgKBkc7:TR?= MnLnOFghcA>? MXjEUXNQ NVLSNpg4cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NXXUXldQOjV7NES1OlY>
OS17 NWHzbYI2SXCxcITvd4l{KEG|c3H5 M3HCdFHjiIoQvF2= MV20PEBp Mn\XSG1UVw>? NE\2b3ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> M4PxNFI2QTR2NU[2
MOLM13 MlnhRZBweHSxc3nzJGF{e2G7 NH;1OGkzPTBibl2= NVTIUoJGPDhiaB?= MlfhSG1UVw>? MVXpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? MUSyOVA2Ozh{NR?=
MV4-11  MVrBdI9xfG:|aYOgRZN{[Xl? NXTSeVlNOjVyIH7N NVTxRmdUPDhiaB?= NGfMOmtFVVOR NWLPS3IzcW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIH1bZpienSrbnni NWPjUIpSOjVyNUO4NlU>
MOLM13 MUjGeY5kfGmxbjDBd5NigQ>? NXixe5VGOjVyIH7N M3vkdFI1KGh? MXHEUXNQ NHj6VXBmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= MmPoNlUxPTN6MkW=
MV4-11  NUmw[FdPTnWwY4Tpc44hSXO|YYm= MonqNlUxKG6P NHHvZlEzPCCq NV7rNnYxTE2VTx?= Mnux[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS MoXFNlUxPTN6MkW=
MOLM13 MWnBdI9xfG:|aYOgRZN{[Xl? MV[yOVAhdk1? Mn:xOFghcA>? NXzlRotPTE2VTx?= MkXNbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? NGPxe4ozPTB3M{iyOS=>
MV4-11  NFuxcFlCeG:ydH;zbZMhSXO|YYm= NFLwc40zPTBibl2= NYTQcJpKPDhiaB?= M2TYRmROW09? M4TnXIlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? M4\VW|I2ODV|OEK1
Hela M4LnXGNmdGxiVnnhZoltcXS7IFHzd4F6 M3zFW|AuPTByIH7N NIjPbpY4OiCq NF7LU29FVVOR NWLyUVU6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlLKNlUxODl{OUW=
HBL-1 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHTOXmMxNTVyMDDuUS=> M33wZVczKGh? NGX0NY1FVVOR M3u0foRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUOyOVAxQTJ7NR?=
HLY-1 NGKzOGRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV[wMVUxOCCwTR?= NULIbZR2PzJiaB?= M2XNb2ROW09? M1;WRYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mnz6NlUxODl{OUW=
OCI-Ly3 M4m5WGNmdGxiVnnhZoltcXS7IFHzd4F6 MXSwMVUxOCCwTR?= NHq1cpU4OiCq MmDZSG1UVw>? NXrsbFlr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlvBNlUxODl{OUW=
OCI-Ly10 MkL6R4VtdCCYaXHibYxqfHliQYPzZZk> MlLhNE02ODBibl2= M3GzO|czKGh? M3i3bmROW09? M4q2c4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoXRNlUxODl{OUW=
SU-DHL-4 NWSzVVZNS2WubDDWbYFjcWyrdImgRZN{[Xl? M4PsV|AuPTByIH7N Moj5O|IhcA>? NIjEOpJFVVOR MW\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXSyOVAxQTJ7NR?=
SU-DHL-5 NWCwWFZyS2WubDDWbYFjcWyrdImgRZN{[Xl? NH;KWnQxNTVyMDDuUS=> MlXiO|IhcA>? NGfoe2dFVVOR Mki1[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYWyOVAxQTJ7NR?=
SU-DHL-6 NUjaRWh1S2WubDDWbYFjcWyrdImgRZN{[Xl? MlPONE02ODBibl2= MnjoO|IhcA>? M17o[WROW09? NIrTTGJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGHMUHYzPTByOUK5OS=>
SU-DHL-10 MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYK0fHlLOC13MECgcm0> NX;kbmpsPzJiaB?= MYHEUXNQ MYrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NV\jUJRVOjVyMEmyPVU>
RC-K8 MlnNR4VtdCCYaXHibYxqfHliQYPzZZk> MmK3NE02ODBibl2= NGDjSYE4OiCq NYTER2tCTE2VTx?= M2LGS4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUSyOVAxQTJ7NR?=
OCI-Ly8 NYrvVHE6S2WubDDWbYFjcWyrdImgRZN{[Xl? M2j4V|AuPTByIH7N MVK3NkBp MkDlSG1UVw>? M2PQPYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWrIR3d1OjVyMEmyPVU>
OCL-Ly18 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV[wMVUxOCCwTR?= NFHUbGk4OiCq NYrldWFXTE2VTx?= NVjD[nQ{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NF\ndI8zPTByOUK5OS=>
OCI-Ly3 NGe3U3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LRcFE4Oi9{NUCvOVAxKG6P NXPzUm41Oi95IHS= NYTzeIlZTE2VTx?= MVXpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NG\je3QzPTByOUK5OS=>
OCI-Ly8 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDPb5kyPzJxMkWwM|UxOCCwTR?= Ml3PNk84KGR? NFnOOZhFVVOR NGHyelFqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg MkXFNlUxODl{OUW=
SU-DHL-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfnb2MyPzJxMkWwM|UxOCCwTR?= MlXmNk84KGR? NIHxWJhFVVOR MULpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NFTkOmMzPTByOUK5OS=>
SU-DHL-10 NF32eItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexO|IwOjVyL{WwNEBvVQ>? M3PseFIwPyCm NVr3Z|VRTE2VTx?= NH3UdIxqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NWj4fZp6OjVyMEmyPVU>
OCI-Ly3 MXLBdI9xfG:|aYOgRZN{[Xl? NGn5SWsyPzJxMkWwJI5O MX:3[C=> NXP0V4tZTE2VTx?= MmXrbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MnTJNlUxODl{OUW=
OCI-Ly8 NE\5WIJCeG:ydH;zbZMhSXO|YYm= M2HJUlE4Oi9{NUCgcm0> MkXvO4Q> NX63V|ZzTE2VTx?= NVzRZZJNcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NWLoUGJ4OjVyMEmyPVU>
SU-DHL-4 NXrFdZU2SXCxcITvd4l{KEG|c3H5 NF;Od5gyPzJxMkWwJI5O M{G3OVdl NU\ndGhvTE2VTx?= NG\2cotqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> MUiyOVAxQTJ7NR?=
SU-DHL-10 MV7BdI9xfG:|aYOgRZN{[Xl? MWSxO|IwOjVyIH7N NYnxOZJlP2R? NWTofJRTTE2VTx?= MofMbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NWXCdFJEOjVyMEmyPVU>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID